Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL1728893 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL4920513 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL7537653 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL5679533 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL703430 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL509509 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL723498 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL2392102 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL37333 | 1.00 | — | — | |
| Methylene Chloride SCHEMBL2350111 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3888658-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-03-09 | — | — | US | disclosed |
| EP-3888658-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3380101-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20200339590-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | eFector Therapautics, Inc. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10577378-B2 | EIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180298017-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| EP-2352201-B1 | DYE, PHOTOELECTRIC CONVERSION ELEMENT AND PHOTOELECTROCHEMICAL CELL EACH COMPRISING THE DYE, AND PROCESS FOR PRODUCING DYE | FUJIFILM CORP (JP) | 2018-10-17 | — | — | EP | disclosed |
| EP-3380101-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2018-10-03 | — | — | EP | disclosed |
| US-9957277-B2 | eIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2017091585-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| EP-2845882-A2 | Dye, Photoelectric Conversion Element and Photoelectrochemical Cell | Fujifilm Corporation (JP) | 2015-03-11 | — | — | EP | disclosed |
| US-8779126-B2 | Dye, photoelectric conversion element using the same, photoelectrochemical cell, and method of producing dye | FUJIFILM CORPORATION (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20110213144-A1 | DYE, PHOTOELECTRIC CONVERSION ELEMENT USING THE SAME, PHOTOELECTROCHEMICAL CELL, AND METHOD OF PRODUCING DYE | FUJIFILM CORPORATION (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2352201-A1 | DYE, PHOTOELECTRIC CONVERSION ELEMENT AND PHOTOELECTROCHEMICAL CELL EACH COMPRISING THE DYE, AND PROCESS FOR PRODUCING DYE | FUJIFILM Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339590-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | TSHR 3587/4885TDP1 568/4885TP53 927/4885 |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | TSHR 3587/4885TDP1 568/4885TP53 927/4885 |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | TSHR 3587/4885TDP1 568/4885TP53 927/4885 |
| US-20110213144-A1 | DYE, PHOTOELECTRIC CONVERSION ELEMENT USING THE SAME, PHOTOELECTROCHEMICAL CELL, AND METHOD OF PRODUCING DYE | CYBA, SCN3A, CRY1 | TSHR 2801/4885TDP1 2439/4885TP53 1584/4885 |
| US-20180298017-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | TSHR 3587/4885TDP1 568/4885TP53 927/4885 |
| US-10577378-B2 | EIF4A-inhibiting compounds and methods related thereto | EIF4A1, EIF4A2, EIF4A3 | TSHR 3587/4885TDP1 568/4885TP53 927/4885 |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | TSHR 3587/4885TDP1 568/4885TP53 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.